JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
QUICK SEARCH:   [advanced]


     

First published online January 16, 2008
J Nucl Med 2008, doi:10.2967/jnumed.107.045526
 © 2008 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.107.045526v1
49/2/255    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beer, A. J.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beer, A. J.
Right arrow Articles by Schwaiger, M.

Patterns of {alpha}v{beta}3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET

Ambros J. Beer 1*, Markus Niemeyer 2, Janette Carlsen 1, Mario Sarbia 3, Jörg Nährig 3, Petra Watzlowik 1, Hans-Jürgen Wester 1, Nadia Harbeck 2, and Markus Schwaiger 1

1 Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
2 Department of Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
3 Department of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

* To whom correspondence should be addressed. E-mail: beer{at}roe.med.tum.de.


  Abstract

The integrin {alpha}v{beta}3 is a key player in angiogenesis and metastasis. Our aim was to study the uptake patterns of the {alpha}v{beta}3-selective PET tracer 18F-galacto-RGD in invasive ductal breast cancer. Methods: Sixteen patients with primary (n = 12) or metastasized breast cancer (n = 4) were examined with 18F-galacto-RGD PET. Standardized uptake values (SUVs) were derived by region-of-interest analysis, and immunohistochemistry of {alpha}v{beta}3 expression was performed (n = 5). Results: 18F-Galacto-RGD PET identified all invasive carcinomas, with SUVs from 1.4 to 8.7 (mean ± SD, 3.6 ± 1.8; tumor-to-blood and tumor-to-muscle ratios, 2.7 ± 1.6 and 6.2 ± 2.2, respectively). Lymph-node metastases were detected in 3 of 8 patients (mean SUV, 3.3 ± 0.8). SUVs in distant metastases were heterogeneous (2.9 ± 1.4). Immunohistochemistry confirmed {alpha}v{beta}3 expression predominantly on microvessels (5/5) and, to a lesser extent, on tumor cells (3/5). Conclusion: Our results suggest generally elevated and highly variable {alpha}v{beta}3 expression in human breast cancer lesions. Consequently, further imaging studies with 18F-galacto-RGD PET in breast cancer patients for assessment of angiogenesis or planning of {alpha}v{beta}3-targeted therapies are promising.

Key Words: breast cancer, integrins, {alpha}v{beta}3, angiogenesis, PET, RGD




This article has been cited by other articles:


Home page
 JNMHome page
M. S. Morrison, S.-A. Ricketts, J. Barnett, A. Cuthbertson, J. Tessier, and S. R. Wedge
Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy
J. Nucl. Med., January 1, 2009; 50(1): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. R. Hsu and X. Chen
Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis
J. Nucl. Med., April 1, 2008; 49(4): 511 - 514.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.